

CURRICULUM VITAE – Dott.sa TETIANA SKRYPETS

INFORMAZIONI PERSONALI

Cognome/Nome: Skrypets Tetiana

Luogo e data di nascita: Sebastopoli (Ucraina) 01/08/1990

Cittadinanza: Ucraina

Contatti: tetianaskrypets@gmail.com

ESPERIENZA PROFESSIONALE

Carriera accademica ed ospedaliera

2022 – oggi: Borsa di studio per lo svolgimento delle attività di studio e ricerca relative al progetto "Ospedale diffuso per l'ematologia" presso l'U.O. di Ematologia dell'IRCCS Istituto Tumori "Giovanni Paolo II" di Bari

2019-2022: Attività clinico-assistenziale nell'ambito della attività di ricerca di Dottorato presso l'U.O. di Ematologia dell'IRCCS Istituto Tumori "Giovanni Paolo II" di Bari (frequenza volontaria).

2018-2022: Dottorato di ricerca in Medicina Clinica e Sperimentale, presso l'Università degli studi di Modena e Reggio Emilia, discutendo la tesi dal titolo: "T-CELL PROJECT: Il valore dei registri linfomi a cellule T periferiche" (Tutor: Prof. Massimo Federico)

2015-2018: Medico ricercatore, Dipartimento di ematologia-oncologia presso l'Istituto Nazionale Oncologico, Kyiv, Ucraina.

2015-2017: Medico dirigente, Dipartimento di ematologia-oncologia presso l'Istituto Nazionale Oncologico, Kyiv, Ucraina.

ISTRUZIONE E FORMAZIONE

Laurea

11/2018-09/2022: Dottorato di ricerca in Medicina Clinica e Sperimentale, presso l'Università degli studi di Modena e Reggio Emilia, discutendo la tesi dal titolo: "T-CELL PROJECT: Il valore dei registri linfomi a cellule T periferiche" (Tutor: Prof. Massimo Federico)

Titolo conseguito - PhD
27/05/2022 (A.A 2018-2022)

02/2019-11/2020: Certificato di Competenza nell'ambito dei linfomi (CCL4 Master) Scuola Europea di Oncologia ed Università di Ulm, Germania

16/05/2017: Scuola di **specializzazione in ematologia** presso l'Accademia Nazionale di Shupyk (NMAPE), Kyiv, Ucraina

Titolo conseguito - Specializzazione in ematologia

11-12/2017: Clinica del Dipartimento di Medicina Diagnostica, Clinica e di Sanità Pubblica dell'Università di Modena e Reggio Emilia, Modena, Italy

11-12/2015: Training program in hematology/oncology and BMT (Würzburg, Germania), Clinica universitaria, dipartimento di oncologia/ematologia.

30/04/2015: Scuola di **specializzazione in Oncologia Clinica** presso l'Università di Medicina di O. Bogomolets, Kyiv, Ucraina

Titolo conseguito - Specializzazione in Oncologia Clinica
06/05/2015 (A.A 2013-2015)

07/2013: European CanCer Organization (ECCO), Elective course in oncology for medical students (Antwerp, Belgium)

06/2013: **Laurea in Medicina e chirurgia generale** presso l'Università di Medicina di O. Bogomolets, Kyiv, Ucraina

Titolo conseguito – Laurea in Medicina generale
21/06/2013 (A.A 2007-2013)

Lingue

1. **Ucraino** – madrelingua
2. **Russo** – madrelingua
3. **Inglese C1** (Advanced) – British Council Certificate
4. **Italiano C1** (Advanced) – Certificato CILS
5. **Tedesco A2** (Pre intermediate)

PROGETTI DI RICERCA IN CORSO E COLLABORAZIONI SCIENTIFICHE ATTIVE

Dal 2018 – T-Cell Lymphoma Project 2.0 (>150 centri internazionali, 26 paesi del mondo, Associazione Angela Sera)

Dal 2019 – Ukrainian Lymphoma Registry (Istituto Oncologico, Kyiv)

Dal 2021 – Histological Revision in T-Cell Lymphoma Project 2.0

Dal 2021 – Valutazione multifattoriale delle alterazioni della sessualità nei pazienti con linfoma

Dal 2022 – FDG PET evaluation in Peripheral T Cell Lymphoma and its prognostic role: an international multicenter analysis by the TCP2.0 Investigators

Dal 2022 – Revisione istologica nei linfomi T nell'ambito del T-Cell Project 2.0

Dal 2022 – Collaborazioni con Lymphoma Coalition Europe

Dal 2023 – Burkitt Lymphoma International Prospective Registry (Dana Farber Cancer Institute, Amsterdam UMC, Brown University and Associazione Angela Sera)

Dal 2023 - Research project to validate prospectively the use of simplified geriatric assessment (sGA) and to integrate it in prognostic models for elderly patients with PTCLs.

Since 2024 – Responsabile for Cantera Club

RELAZIONI A CONGRESSI NAZIONALI e
INTERNAZIONALI

2024

1. T-Cell Projects: Dante, Virtual review, Mature, PET, EBV – **Polish Lymphoma Group Meeting, Warsaw, Poland**
2. PLATO: Post Transplant Lymphoproliferative Disorders Project – **Amerigo Vespucci Investigator meeting, Buenos-Aires, Argentina**
3. PET in TCP 2.0 (T-Cell Lymphoma Project) – **Investigator Meeting, Buenos-Aires, Argentina**

2023

4. Diffuse large b-cell lymphoma – EHA congress updates – **Congresso QOL-ONE: Aggiornamenti dall'EHA 2023, Reggio Calabria, Italy**
5. The relevance of lymphoma registries – **as special coaches of EHA-TSH "La Cantera" on Indolent lymphomas, Ankara, Turkey**
6. Indolent lymphomas. WHO 2022 - **as special coaches of EHA-TSH "La Cantera" on Indolent lymphomas, Ankara, Turkey**
7. Proteasome inhibitors in Multiple Myeloma treatment - Ixazomib – **Takeda Advisory Board, Kyiv, Ukraine (online)**
8. Le strategie di cura del DLBCL R/R: dalla letteratura alla pratica clinica – **LYMPHOMA DAY, Reggio Calabria, Italy**
9. T-Cell Project 2.0 and PET in PTCL - **Meeting Scientifico Associazione Italo-Brasiliana di Ematologia (AIBE) Palazzo Vistarino, Pavia, Italy**
10. T-Cell Project 2.0 - **Yearly Meeting of the EHA Lymphoma Group, Dubrovnik, Croatia**
11. Updates on Diffuse Large B Cell Lymphoma - **TSH-ISH Joint Virtual Course on Hematological Malignancies, Turkey (online).**

2022

1. The SALENTO Prognostic Model - Developed on 244 Cases Enrolled in the T Cell Project 1 By the International T Cell Project Network – **ASH 2022, New Orleans, USA**
2. Proteasome inhibitors in Multiple Myeloma treatment – **International Hematological Conference, Kyiv, Ukraine (online)**
3. T-Cell Project – **Commissione FIL Linfomi T (online)**
4. T-Cell Projects: Dante. Virtual Review. PET. Mature - **Yearly Meeting of the EHA Lymphoma Group, Amsterdam, Netherlands.**
5. L'evoluzione delle cure nel mondo dei Linfomi – **Linfovita, Locride, Italia**
6. Caso clinico DLBCL – **Eppur si muove, Bari, Italia**
7. Caso clinico Linfoma T (hepatosplenic) – **Lyfe course, Bellinzona, Svizzera**

2021

1. Peripheral T-cell Lymphomas: Where we have been and where are we going? – **6th Edition. Insights in Hematology, Cluj-Napoca, Romania**

2. Comprensione dei sintomi e urgenza della diagnosi – ***Giornata mondiale della consapevolezza sui linfomi, Reggio Calabria, Italia***
3. COVID-19. Vaccination of oncohematology patients – ***Oncological Forum, Kyiv, Ukraine (online)***
4. Management of patients with cutaneous T-cell lymphomas. The importance of T-cell lymphoma registries – ***Important questions in oncodermatology, Kyiv, Ukraine (online)***
5. Proteasome inhibitors in Multiple Myeloma treatment – ***International Hematological Conference, Kyiv, Ukraine (online)***

2020

1. Caso clinico Linfoma T (ALCL, ALK-) – ***Lyfe course, Bellinzona, Svizzera***
2. Linfomi non Hodgkin T: dal T-cell project alla pratica clinica – ***LLC, LF, DLBCL. Trattamento attuale e reali prospettive a breve termine (online)***

MEMBERSHIP IN SOCIETÀ SCIENTIFICHE

1. American Society of Clinical Oncology (ASCO)
2. European Society of Medical Oncology (ESMO)
3. European Haematology Association (EHA)
4. Fondazione Italiana Linfomi (FIL)
5. Ukraine Association of Oncohematology

PREMI/RICONOSCIMENTI

1. Travel Grant. Elective course in oncology for medical students (Belgium), 2013
2. Travel Grant. EHA-AHA Tutoria. Diagnosis, Prognosis and Management of Hematologic Malignancies (Armenia), 2015
3. Fryderyk teodor oehme travel grant (Poland), 2015
4. Travel Grant. ESMO Preceptorship meeting in Lymphomas (Switzerland). 2015
5. Travel Grant. ESMO Preceptorship meeting in Immuno-Oncology (Czech Republic), 2015
6. Travel Grant. 2nd Masterclass on Systematic Reviews in Cancer Care, Guidelines and Research (UK), 2016
7. EACS scholarship. 16th European AIDS Conference (Italy), 2017
8. Travel Grant. ESH 4th International Conference on hematologic malignancies at older age: biology and therapy (France), 2018
9. Young Investigator Grant, SOHO (USA), 2019
10. Certificate of Competence in Lymphoma course at Ulm University in collaboration with the European School of Oncology (1,5 year course), 2019-2020
11. Travel Grant. LyFe Forum of Excellence (Switzerland), 2020
12. Travel Grant. EHA 2020, 2020
13. Young Investigator Grant, SOHO (USA), 2020

14. Young Investigator Grant, SOHO (USA), 2021
15. Premio Dott. Giuseppe Luppi per la contribuzione alle attività di ricerca nel campo dei linfomi maligni (Italy), 2021
16. Young Investigator Grant, SOHO (USA), 2023
17. Grant for 9-month program in Clinical Research Trial in Hematology (CRTH) by European Hematology Association (EHA), 2023-2024

ATTIVITÀ EDITORIALE

Revisore per riviste internazionali: British Journal of Hematology, Frontiers, Cancers, Medicina

Publicazioni scientifiche in estenso

Autore delle pubblicazioni su riviste internazionali con impact factor riportate in seguito, tra cui articoli editi a primo e ultimo nome. Autore di oltre 40 abstracts presentati a congressi nazionali e internazionali

H-index 8 (citations 424)

<https://scholar.google.com/citations?user=fXSrYykAAAAJ>

1. Civallero M, Schroers-Martin JG, Horwitz S, Manni M, Stepanishyna Y, Cabrera ME, Vose J, Spina M, Hitz F, Nagler A, Montoto S, Chiattonne C, **Skrypets T**, Perez Saenz MA, Priolo G, Luminari S, Lymboussaki A, Pavlovsky A, Marino D, Liberati M, Trotman J, Mannina D, Federico M, Advani R.
Long-term outcome of peripheral T-cell lymphomas: Ten-year follow-up of the International Prospective T-cell Project. Br J Haematol. 2024 Mar 26. doi: 10.1111/bjh.19433. Epub ahead of print. PMID: 38532575.
2. Stepanishyna Y, Manni M, Civallero M, Shokun N, **Skrypets T** et al.
Outcome of malignant lymphoma in Ukraine. Analysis of 563 cases registered in the Ukrainian Lymphoma Registry in 2019-2021. Br J Haematol. 2024 Feb 23. doi: 10.1111/bjh.19352. Epub ahead of print. PMID: 38400556.
3. Hapgood G, Civallero M, Stepanishyna Y, Vose JM, Cabrera ME, Advani RH, Pileri SA, Manni M, Horwitz SM, Foss FM, Hitz F, Radford J, Dlouhy I, Chiattonne CS, Kim WS, **Skrypets T**, Nagler A, Trotman J, Luminari S, Federico M.
The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network. Blood Adv. 2023 May 10:bloodadvances.2023010037. doi: 10.1182/bloodadvances.2023010037. Epub ahead of print. PMID: 37163360.

4. Nizzoli ME, Manni M, Ghiggi C, Pulsoni A, Musuraca G, Merli M, Califano C, Bari A, Massaia M, Conconi A, Musto P, Mannina D, Perrone T, Re F, Galimberti S, Gini G, Capponi M, Vitolo U, Usai SV, Stefani PM, Ballerini F, Liberati AM, Pennese E, Pastore D, **Skrypets T**, Catellani H, Marcheselli L, Federico M, Luminari S. **Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi.** Hematol Oncol. 2023 May 28. doi: 10.1002/hon.3184. Epub ahead of print. PMID: 37246287.
5. Kriachok I, Stepanishyna Y, **Skrypets T**, Shokun N, Martynchuk A, Tytorenko I, Aleksik O, Krotevych M, Manni M, Federico M. **Distribution of lymphoma subtypes in Ukraine according to the WHO 2016 classification.** Hematol Oncol. 2022 Aug 6. doi: 10.1002/hon.3061. Epub ahead of print. PMID: 35932211.
6. Luminari S, Manni M, Galimberti S, Versari A, Tucci A, Boccomini C, Farina L, Olivieri J, Marcheselli L, Guerra L, Ferrero S, Arcaini L, Cavallo F, Kovalchuk S, **Skrypets T**, Del Giudice I, Chauvie S, Patti C, Stelitano C, Ricci F, Pinto A, Margiotta Casaluci G, Zilioli VR, Merli A, Ladetto M, Bolis S, Pavone V, Chiarenza A, Arcari A, Anastasia A, Dondi A, Mannina D, Federico M; Fondazione Italiana Linfomi. **Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study.** J Clin Oncol. 2022 Mar 1;40(7):729-739. doi: 10.1200/JCO.21.01234. Epub 2021 Oct 28. PMID: 34709880.
7. Gabus R, Pavlovsky A, Eleta M, **Skrypets T**, Kryachok I, Novosad O, Stepanishyna Y, Kmetyuk Y, Alaskar A, Shaheen N, Ali SA, Al-Mansour M, Bergesio F, Chauvie S. **PET/CT Imaging of Lymphoma Outside the Western World.**
In: Gallamini A, Juweid M, editors. Lymphoma [Internet]. Brisbane (AU): Exon Publications; 2021 Dec 28. Chapter 7. PMID: 35226436.
8. Luminari S, Manni M, Galimberti S, Versari A, Tucci A, Boccomini C, Farina L, Olivieri J, Marcheselli L, Guerra L, Ferrero S, Arcaini L, Cavallo F, Kovalchuk S, **Skrypets T**, Del Giudice I, Chauvie S, Patti C, Stelitano C, Ricci F, Pinto A, Margiotta Casaluci G, Zilioli VR, Merli A, Ladetto M, Bolis S, Pavone V, Chiarenza A, Arcari A, Anastasia A, Dondi A, Mannina D, Federico M; Fondazione Italiana Linfomi. **Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study.** J Clin Oncol. 2022 Mar 1;40(7):729-739. doi: 10.1200/JCO.21.01234. Epub 2021 Oct 28. PMID: 34709880.
9. Oliva S, Puzzovivo A, Gerardi C, Allocati E, De Sanctis V, Minoia C, **Skrypets T**, Guarini A, Gini G. **Late Cardiological Sequelae and Long-Term Monitoring in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi.** Cancers (Basel).

2021 Dec 23;14(1):61. doi: 10.3390/cancers14010061. PMID: 35008222; PMCID: PMC8750391.

10. **T.Skrypets**, M. Manni, M. Civallero. I. Kriachok, M. Federico
The Value and Relevance of T-cell Lymphoma Registries. The Peripheral T-Cell Lymphomas (eds O.A. O'Connor, W.S. Kim and P.L. Zinzani). <https://doi.org/10.1002/9781119671336.ch26>
11. Luminari S, **Skrypets T.**
What's new in peripheral T-cell lymphomas. Hematol Oncol. 2021 Jun;39 Suppl 1:52-60. doi: 10.1002/hon.2846. PMID: 34105820.
12. Rossini B, Skrypets T, Minoia C, Quinto AM, Zaccaria GM, Ferrari C, Maggialelli N, Mastroianni A, Gatti P, Casiello M, Ciavarella S, Guarini A.
Primary, Bilateral and Diffuse Renal Non-Hodgkin's Lymphoma in a Young Woman Suffering from Turner Syndrome. J Pers Med. 2021 Jul 7;11(7):644. doi: 10.3390/jpm11070644. PMID: 34357111; PMCID: PMC8305304.
13. Shustov A, Cabrera ME, Civallero M, Bellei M, Ko YH, Manni M, **Skrypets T**, Horwitz SM, De Souza CA, Radford JA, Bobillo S, Prates MV, Ferreri AJM, Chiattoni C, Spina M, Vose JM, Chiappella A, Laszlo D, Marino D, Stelitano C, Federico M. **ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project.** Blood Adv. 2021 Feb 9;5(3):640-648. doi: 10.1182/bloodadvances.2020001581. PMID: 33560375; PMCID: PMC7876884.
14. **Skrypets T**, Ferrari C, Nassi L, Margiotta Casaluci G, Puccini B, Mannelli L, Filonenko K, Kryachok I, Clemente F, Vegliante MC, Daniele A, Sacchetti G, Guarini A, Minoia C. **18F-FDG PET/CT Cannot Substitute Endoscopy in the Staging of Gastrointestinal Involvement in Mantle Cell Lymphoma. A Retrospective Multi-Center Cohort Analysis.** J Pers Med. 2021 Feb 13;11(2):123. doi: 10.3390/jpm11020123. PMID: 33668644; PMCID: PMC7918751.
15. Ranjana H. Advani, **Tetiana Skrypets**, Monica Civallero, Michael A. Spinner, Martina Manni, Won Seog Kim, Andrei R. Shustov, Steven M. Horwitz, Felicitas Hitz, Maria Elena Cabrera, Ivan Dlouhy, Josè Vassallo, Stefano A. Pileri, Giorgio Inghirami, Silvia Montoto, Umberto Vitolo, John Radford, Julie M. Vose, and Massimo Federico *on behalf of the T-cell Lymphoma Project.* **Outcomes and Prognostic Factors in Angioimmunoblastic T-cell Lymphoma: Final Report from the Prospective International T-cell Project.** Blood. 2021 Mar 30;blood.2020010387. doi: 10.1182/blood.2020010387. Epub ahead of print. PMID: 33786592.
16. Fox CP, Civallero M, Ko YH, Manni M, **Skrypets T** et al.
Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project [published online ahead of print, 2020 Feb 24].

Lancet Haematol. 2020;S2352-3026(19)30283-2. doi:10.1016/S2352-3026(19)30283-2

17. Opinto G, Vegliante MC, Negri A, **Skrypets T** et al.
The Tumor Microenvironment of DLBCL in the Computational Era. *Front Oncol.* 2020;10:351. Published 2020 Mar 31.
doi:10.3389/fonc.2020.00351
18. Silvestris E, Cormio G, **Skrypets T**, et al.
Novel aspects on gonadotoxicity and fertility preservation in lymphoproliferative neoplasms. *Crit Rev Oncol Hematol.* 2020;151:102981. doi:10.1016/j.critrevonc.2020.102981
19. **T. Skrypets**, O. Novosad, Y. Pastushenko, O. Gorbach, I. Kriachok,
Ukraine Data on Prognostic Factors and Treatment Outcomes in Patients with Peripheral T-Cell Lymphomas.
Klin Onkol 2019; 32(6): 436-444
doi: 10.14735/amko2019436
20. Federico M., Caballero Barrigòn M.D., Marcheselli L., Tarantino V., Manni M., Sarkozy C., Alonso-Alvarez S., Wondergem M., Cartron G., Lopez-Guillermo A., Issa D., Morschhauser F., Alcoceba M., Kimby E., Rusconi C., Chamuleau M., Holte H., Lockmer S., Montoto S., Gomes da Silva M., Aurer I., Zuzza E., Paszkiewicz-Kozik E., **Skrypets T.**, Blaker Y.N., Salles G., Coiffier B.,
Aristotle Consortium: Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis
The Lancet Haematology (ISSN ISSN 2352-3026), 5:8-e359:e367, 2018
doi: 10.1016/S2352-3026(18)30090-5
21. Novosad O, **Skrypets T**, Pastushenko Y, Titorenko I, Martynchuk A, Skachkova O, Inomistova M, Gorbach A, Khranovska N, Kryachok I.
MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis.
Klin Onkol. Spring 2018;31(2):130-136.
doi: 10.14735/amko2018130.
22. Novosad O, **Skrypets T**, Pastushenko I, Kadnikova T, Gorbach O, Kozlov V, Mykhalska L, Kosinova V, Kostiukova N, Karnabeda O, Stratienko V, Novikov M, Oliinichenko O, Kmetyuk I, Karpova O, Ashykhmin A, Lukjanec O, Kriachok I. **A Ukrainian multicenter prospective study of the value of PET/ CT prognostic role in primary patients with Hodgkins lymphoma in a real-life cohort.** *Klin Onkol.* 2020 Winter;33(6):450-457. English. PMID: 33685195.

Abstracts

1. T. Skrypets et al
Baseline pet total metabolic tumor volume has a prognostic role in PTCLs – data from international prospective t-cell project 2.0
EHA Congress 2024, Madrid, Spain (*Accepted as poster*)
2. Maria Elena Cabrera, Lea Derio, Yana Stepanishyna, Monica Civallero, **Tetiana Skrypets**, Martina Manni, Massimo Federico
Long-term cause-specific mortality in a cohort of 1,435 hodgkin lymphomas treated at the national adult public cancer program in Chile over a 30-year period.
EHA Congress 2024, Madrid, Spain (*Accepted as poster*)
3. Manuel Gotti, Yana Stepanishyna, Luigi Marcheselli, **Tetiana Skrypets**, Caterina Cristinelli, Umberto Ricardi, Martin Hutchings, Julien Lazarovici, Francesco Merli, Sanne Tonino¹, Jean Marc Schiano De Colella, Catherine Fortpied, Luigi Rigacci, Wouter Plattel, Marc André, Massimo Federico
Outcome of patients with limited-stage hodgkin lymphoma (HL) enrolled in the EORTC/LYSA/FIL H10 and progressed/relapsed after initial therapy
EHA Congress 2024, Madrid, Spain (*Accepted as poster*)
4. T. Skrypets, A. Passiatore, F. Pavone, G. Loseto, E. Silvestris, F. Lagattolla, A. Ritella, F. Romito, A. Guarini, C. Minoia
Multifactorial evaluation of sexuality alterations in patients treated for lymphoma
Societa Italiana Ematologica, 26-28 September 2023, Rome, Italy (*Accepted as poster*)
5. Skrypets Tetiana, Federico Massimo, Lemonnier Francois, Tilly Hervé on behalf of the European Lymphoma Institute
Global Perspectives on T-Cell Lymphoma. A proposed road map
SOHO 2023, 6-9 September, 2023, Houston, USA (*Accepted as poster*)
6. **Tetiana Skrypets**, Stephane Chauvie, Martina Manni, Federico Fallanca, Manuela Racca, Felicitas Hitz, Ranjana Advani, Celso Dario Ramos, Eliana Miranda, Ciprian Tomuleasa, Carla Minoia, Dario Marino, Figen Noyan-Atalay, Yana Stepanishyna, Adriano De Maggi, Luigi Marcheselli, Cheryl Chang, Massimo Federico and Stefano Luminari.
Baseline PET Total Metabolic Tumor Volume has a prognostic role in PTCLs – Data from International Prospective T-Cell Project 2.0
17th ICML, 13-17 June, 2023, Lugano, Switzerland (*Accepted as poster*)
7. M. Manni, C. S. Chiattonne, H. M. Prince, A. Pavlovsky, C. Tomuleasa, E. Miranda, I. Kriachok, E. A. Hawkes, L. Fiad, F. Hitz, O. Alpdogan, R. Nair, R. Advani, C. Minoia, S. Horwitz, M.E. Cabrera, J.M. Vose, A. Lymboussakis, M. Civallero, **T. Skrypets**, Y. Stepanishyna, M. Federico and S. Luminari
Mature T and NK cell lymphomas classified according to 2016 WHO

classification. A report of 741 cases registered in the International Prospective T-cell Project 2.0.

17th ICML, 13-17 June, 2023, Lugano, Switzerland (*Accepted as poster*)

8. Civallero M, Advani R, Horwitz S, Manni M, Cabrera ME, Vose J, Spina M, Hits F, Nagler A, Montoto S, Miranda E, **Skrypets T**, Perez Saenz MA, Priolo G, Luminari S, Lymboussakis A, Pavlovsky A, Marino D, Liberati M, Trotman J, Mannina D¹ and Federico M

Long term outcome of Peripheral T Cell Lymphomas:10y follow-up analysis of the International Prospective T Cell Project Network.

17th ICML, 13-17 June, 2023, Lugano, Switzerland (*Accepted as poster*)

9. Gian Maria Zaccaria, Francesco Berloco, Felice Clemente, Anita Susanna Pappagallo, Maria Carmela Vegliante, Grazia Gargano, Paolo Mondelli, Giacomo Volpe, Antonella Bucci, **Tetiana Skrypets**, Carla Minoia, Angela Maria Quinto, Giacomo Loseto, Bernardo Rossini, Fabio Pavone, Anna Scattone, Giuseppe Carella, Vito Angiulli, Chiara Pagani, Alice Di Rocco, Francesca Maria Quagl^{*}, Valentina Tabanelli, Angelo Fama, Benedetta Puccini, Riccardo Moia, Simone Ferrero, Luigi Alfredo Grieco, Simona Colucci, Attilio Guarini, and Sabino Ciavarella.

Validation of ARGO (Automatic record generator for Onco-Hematology), a New App Supporting the Automatic Conversion of Paper-Based reports in standardized e-crfs.

American Society of Hematology (ASH), New Orleans, USA, 8-13 December, 2022 (*Accepted as poster*)

10. Greg Hapgood, Monica Civallero, Yana Stepanishyna, Julie M. Vose, Maria Elena Cabrera, Ranjana H. Advani, Stefano A Pileri, Martina Manni, Steven M. Horwitz, Francine M. Foss, Felicitas Hitz, John Radford, Ivan Dlouhy, Carlos S. Chiattono, Won-Seog Kim, MD, **Tetiana Skrypets**, Arnon Nagler, Judith Trotman, Stefano Luminari and Massimo Federico.

Age, Albumin, and LDH predict outcome of patients with Limited Stage Peripheral T Cell Lymphoma: A Prognostic Model Developed on 244 Cases Enrolled in the T Cell Project 1 By the International T Cell Project Network.

American Society of Hematology (ASH), New Orleans, USA, 8-13 December, 2022 (*Accepted as oral presentation*)

11. Yana Stepanishyna, Iryna Kriachok, Nazar Shokun, Nataliia Shapovalenko, Anisiia Luchkiv, **Tetiana Skrypets**, Martina Manni, and Massimo Federico.

The Dramatic Impact of the War on Access to Treatment for Lymphoma Patients. A Report from the Ukrainian Lymphoma Registry.

American Society of Hematology (ASH), New Orleans, USA, 8-13 December, 2022 (*Accepted as poster*)

12. Massimo Federico, Yana Stepanishyna, **Tetiana Skrypets**, Carlos S Chiattono, Miles H Prince, Astrid Pavlovsky, Athina Lymboussakis, Martina Manni, Monica Civallero, Carmino A De Souza, Eliza A Hawkes, Lorena Fiad,

Reena Nair, Irina Kriachok, Felicitas Hitz, Olga Kostina, Ciprian Tomuleasa, Attilio Guarini, Stefano Luminari.

Mature T and NK cell lymphomas classified according to 2016 WHO classification. A report of the international prospective t-cell project 2.0.

EHA Congress 2022, Viena, Austria (*Accepted as oral presentation*)

13. **Skrypets T.**, Civallero M., Manni M., Vose J.M., Dlouhy I., Pileri S.A., Cabrera M. E., Hitz F., Inghirami G., Bobillo S., Marino D., Advani R., Stelitano C., and Massimo Federico on behalf of the International T Cell Project 1.0

Patterns of care for elderly patients with peripheral T-cell lymphoma: a report from the International T Cell Project 1.0.

SOHO 2021, Houston, USA (Accepted as a poster)

14. C. Minoia, C. Gerardi, E. Allocati, V. De Sanctis, S. Franceschetti, S. Viviani, M. A. Annunziata, A. Bari, **T. Skrypets**, S. Oliva, A. Puzzovivo, S. Di Molfetta, V. Caccavari, A. Di Russo, G. Loseto, A. Daniele, L. Nassi, G. Gini, A. Guarini

Late toxicities and long-term monitoring in classical Hodgkin lymphoma and diffuse large B-cell lymphoma survivors: a series of systematic reviews of the Fondazione Italiana Linfomi

SOHO 2021, Houston, USA (Accepted as a poster)

15. Federico M., Chiattoni C., Prince M., Pavlosky A., Kriachok I., Nair R., Tomuleasa C., Advani R., Manni M., **Skrypets T.**, Civallero M., Galli GR., De Souza C., Luminari S. on behalf of the T Cell Project Consortium.

The T-cell project: where we have been and where are we going?

13th Annual Virtual T-Cell Lymphoma Forum 2021, 8-10 July, USA

16. **Tetiana Skrypets**, Yana Stepanishyna, Giulia Raffaella Galli, Martina Manni, Anna Hubareva, Iryna Tytorenko, Arina Martynchyk, Olena Aleksik, Yan Pastushenko, Nataliia Shudrak, Olga Novosad, Kateryna Filonenko, Tetiana Kadnikova, Yevhen Kushchevyyi, Massimo Federico, Iryna Kriachok.

Subtypes of malignant lymphomas in Ukraine, according to 2016 WHO classification. Preliminary report of the Ukrainian Lymphoma Registry.

16th ICML, 18-22 June, Lugano, Switzerland

17. M. Federico, C. S. Chiattoni, H. M. Prince, A. Pavlovsky, M. Manni, M. Civallero, **T. Skrypets**, C. A. de Souza, E. A. Hawkes, L. Fiad, A. Lymboussakis, C. Tomuleasa, R. Nair, J. Pereira, P. Pereyra, C. Minoia, I. Kriachok, N. S. de Castro, R. H. Advani and S. Luminari.

Subtypes of mature T and NK cell lymphomas according to 2016 WHO classification. Preliminary report of the International

Prospective T-cell Project 2.0. 16th ICML, 18-22 June, Lugano, Switzerland

18. Y. Stepanishyna, **T. Skrypets**, Y. Pastushenko, I. Tytorenko. I. Kriachok.
Analysis of prognostic factors in patients with Primary mediastinal B-cell lymphoma treated by Da-EPOCH-R and R-CHOP.
EHA 2021
19. **Tetiana Skrypets**, Monica Civallero, Martina Manni, Stefano Pileri, Dennis D Weisenburger, Young Hye Ko, Giorgio Inghirami, Mario Bargetzi, Raúl Gabús, Sabela Bobillo Varela, Steven M. Horwitz, Astrid Pavlovsky, Catherine Thieblemont, Carmino Antonio De Souza, Jorge Milone, Won Seog Kim, Silvia Montoto, Kenneth Carson, Julie M. Vose, Massimo Federico, and Ranjana H. Advani, *on behalf of the T-cell Lymphoma Project.*
Angioimmunoblastic T-cell lymphoma: report on 282 cases from the Prospective International T-Cell Lymphoma Project.
SOHO 2020, Houston, USA (Accepted as a poster)
20. **Tetiana Skrypets**, Luca Nassi, Gloria Margiotta Casaluci, Benedetta Puccini, Lara Mannelli, Kateryna Filonenko, Angela Monica Sciacovelli, Maria Carmela Vegliante, Antonella Daniele, Gianmauro Sacchetti, Cristina Ferrari, Irina Kryachok, Attilio Guarini, Carla Minoia
Can 18F-FDG PET/CT overcome endoscopy in the staging of gastrointestinal involvement in mantle cell lymphoma? A retrospective multi-center cohort analysis.
EHA 2020, Francoforte, Germany (Accepted as a poster)
21. Y. Stepanishyna, **T. Skrypets**, O. Novosad and I. Kryachok
Fertility after dose-adjusted EPOCH-R in patients with Primary mediastinal B-cell lymphoma - Ukrainian experience.
EHA 2020, Francoforte, Germany (Accepted as a poster)
22. Olga Novosad , Irina Kryachok, Tatyana Kadnikova, Yan Pastushenko, Olexandr Gorbach, **Tetiana Skrypets**, Oksana Kostiukevych, Ulyana Melnyk, Vitalii Sieriedin, Nina Kostiuikova, Oksana Tkachenko, Larysa Mykhalska, Olha Kylyvnyk, Olena Yamenko
Vcd versus vrd-based regimens as first line therapies in newly diagnosed patients with multiple myeloma (mm): retrospective multicenter analysis.
EHA 2020, Francoforte, Germany (Accepted as a publication)
23. Olga Novosad, Tetiana Skrypets, Oksana Skachkova, Olexandr Gorbach, Nataliia Khranovska, Irina Kryachok
LANGERHANS CELL HISTIOCYTOSIS
EHA 2020, Francoforte, Germany (Accepted as a publication)

24. **Tetiana Skrypets**, Angela Sciacovelli, Sabino Ciavarella, Luca Nassi, Gloria Margiotta Casaluci, Benedetta Puccini, Lara Mannelli, Attilio Guarini and Carla Minoia
Retrospective evaluation of the PET/CT role in gastrointestinal involvement detection in Mantle cell lymphoma
47° Congresso Nazionale della Società Italiana di Ematologia Roma, October 7-9,2019, Rome, Italy
25. **Tetiana Skrypets**, Olga Novosad, Yan Pastushenko and Irina Kryachok.
A single Ukrainian centre experience – comparison of five prognostic scores and treatment outcomes in patients with Peripheral T-cell lymphomas
SOHO 2019, Houston, USA (Accepted as a poster)
26. Andrei Shustov, Maria Elena Cabrera, Monica Bellei, Monica Civallero, Young Hye Ko, Martina Manni, Steven M. Horwitz, Carmino Antonio De Souza, John A. Radford, Sabela Bobillo Varela, Maria Virginia Prates, Andrés J M Ferreri, Carlos Chiattono, Michele Spina, Julie M. Vose, Annalisa Chiappella, Daniele Laszlo, Dario Marino, Caterina Stelitano, **Tetiana Skrypets**, and Massimo Federico *for the T-cell Lymphoma Project study investigators*
Anaplastic Large Cell Lymphoma, ALK-Negative: analysis of 235 Cases collected by the T-Cell Project.
ICML15, 2019, Lugano, Switzerland.(Accepted as a poster)
27. M. Federico, M. Manni, M. Civallero, **T. Skrypets**
The t cell project 2.0: the more we register, the more we learn.
ICML15, 2019 UCLI-ICML JOINT SESSION, Lugano, Switzerland.
28. Olga Novosad, Oleksandr Gorbach, Oksana Skachkova, Ian Pastushenko, Kateryna Ulianchenko, Nataliia Khranovska, **Tetiana Skrypets**, Irina Kryachok; **Role of Circulating Myeloid-Derived Suppressor Cell (MDSC) in Hodgkin Lymphoma (HL) Patients: Prospective Study.**
Blood 2019; 134 (Supplement_1): 5232.
doi: <https://doi.org/10.1182/blood-2019-130852>
ASH 2019, USA
29. O. Novosad, Ia. Pastushenko, **T. Skrypets**, I. Titorenko, T. Kadnikova, O. Skachkova, A. Gorbach, N. Svergun, N. Khranovska, I. Kriachok
Impact of genetic polymorphism on prognosis and survival of diffuse large B-cell lymphoma.
ESMO 2018, Munich, Germany
30. **T. Skrypets**, O. Novosad, I. Pastushenko

PET-CT as a prognostic factor in patients with early stages in primary diagnosed Hodgkin Lymphoma.

ESMO 2018, Munich, Germany

31. O. Novosad, K. Ulianchenko, **T. Skrypets**, T. Kadnikova, I. Kriachok
Assessment to predict survival and risk of progression in patients with newly multiple myeloma according different age groups.
ESMO 2018, Munich, Germany
32. Ia. Pastushenko, **T. Skrypets**, O. Novosad, etc
PET-CT as a prognostic factor in patients with advanced stages in primary diagnosed Hodgkin Lymphoma.
ISHL 2018, Cologne, Germany
33. I. Kriachok, O. Novosad, Ia. Pastushenko, **T. Skrypets** etc.
Multicentre prospective study of quantitative PET values after the end of chemotreatment in primary patients with Hodgkin lymphoma (HL)
7th international workshop on PET in lymphoma and myeloma
Menton, France
34. Federico M., Tarantino V., **Skrypets T.**, Manni M
Program book. 3rd EHA-ISHBT Hematology Tutorial. Lymphoproliferative and Plasma Cell Disorders.
February 16-18, 2018/ Lucknow, India Session 6: Hodgkin Lymphoma
35. **Skrypets T.**, Novosad O., Pastushenko I., et al
Prognostic factors and treatment outcomes in elderly patients with T-Cell non-Hodgkin lymphomas
4th International Conference on hematologic Malignancies at older age: biology and therapy.
March 9-11, 2018/Mandelieu, France Abstract book, Poster 25
36. Novosad O., Ulianchenko K., **Skrypets T.**, et al
Assessment to predict survival and risk of progression in elderly patients with newly Multiple Myeloma.
4th International Conference on hematologic Malignancies at older age: biology and therapy.
March 9-11, 2018/Mandelieu, France Abstract book, Poster 22
37. **Skrypets T.**, Novosad O., Pastushenko I., et al
Prognostic factors and treatment outcomes in patients with peripheral T-cell lymphomas – A single centre experience
Abstract release date: May 17, 2018 EHA Learning Centre. Skrypets T. Jun 14, 2018; 216660
EHA 2018, Stockholm, Sweden
38. Kriachok I., Novosad O., Pastushenko I., **Skrypets T.**, et al

Multicentre study of quantitative PET values in primary patients with Hodgkin lymphoma (HL): Update results

Abstract release date: May 17, 2018) EHA Learning Centre. Kriachok I. Jun 14, 2018; 216035

EHA 2018, Stockholm, Sweden

39. Kryachok, I., Novosad, O., Pastushenko, I., **Skrypets, T.**, Kadnikova, T., Tytorenko, I., ... Danilov, A.
Interim-PET As a Predictive Factor in Patients with Hodgkin Lymphoma.
Blood, 130(Suppl 1), 5186 LP-5186. (2017) Retrieved from http://www.bloodjournal.org/content/130/Suppl_1/5186.abstract
ASH 2017, USA
40. Kryachok I., Novosad O., **T. Skrypets**, et al
Ukrainian Association for helping Patients With Lymphoproliferative Diseases: Patients support care program
Abstract (Poster), ESMO, Annals of Oncology. – № 1464P. – P. 517,
ESMO 2017, Madrid, Spain
41. **Skrypets T.**, Novosad O., Pastushenko I., et al
Evaluation of indoleamine 2,3 –dioxygenase expression (IDO), transforming growth factor beta (TGF- β) and interleukin 13 (IL13) expression on clinical outcome in patients with Hodgkin's lymphoma.
Abstract (Poster), (ESMO), Annals of Oncology. - №1019. – P. 363,
ESMO 2017, Madrid, Spain
42. **Skrypets T.**, Novosad O., Svergun N., et al
The prognostic role of indoleamine 2,3 – dioxygenase expression in Hodgkin's lymphoma
Abstract (Poster), EHA, Hematologica - № 102. – 2017. – P. 500.
EHA 2017, Madrid, Spain
43. Kriachok I., Novosad O., Pastushenko I., **Skrypets T.**, et al
Quantitative PET parameters predicts outcomes in patients with Hodgkin's lymphoma
Abstract (Poster), EHA, Hematologica. – 2017. - №10. – P.463,
EHA 2017, Madrid, Spain
44. I.Kriachok, O. Novosad, **T. Skrypets**
How I treat Waldenström Macroglobulinemia: experience of a site
Display Board: W48
9th International Workshop on Waldenström's Macroglobulinemia and Symposium on Advances in Multiple Myeloma, Amsterdam, The Netherlands, October 5-8, 2016

45. Kryachok I., O. Novosad, **T. Skrypets**, K. Ulianchenko, I. Tytorenko, N. Khranovska, O. Skachkova, N. Svergun, O. Gorbach.
Expression and prognostic impact of indoleamine 2,3-dioxygenase in Hodgkin's lymphoma
The 10th International Symposium on Hodgkin Lymphoma, Cologne, Germany
46. Kryachok I, Ia. Stepanishyna, I. Titorenko, T. Kadnikova, K. Filonenko, **T. Skrypets**, Y. Kushchevyy, I. Pastushenko, O. Aleksik, K. Ulianchenko, O. Novosad, A. Martynchyk
R-da-epoch vs r-chop in patients with primary mediastinal large b-cell lymphoma: results of randomized (prospective) multicenter study. Poster presentation, abstract book №3015
ESMO 2016, Copenhagen, Denmark
47. I. Kryachok, **T. Skrypets**, O. Novosad, N. Khranovska, O. Skachkova, K. Ulianchenko, A.V. Martynchyk, I. Tytorenko, K. Filonenko, I. Stepanishyna, N. Svergun, O. Gorbach, O. Novdah
The role on indoleamine 2,3 – dioxygenase expression in diffuse large B-cell lymphoma prognosis.
Poster presentation, abstract book № 31777
ESMO 2016, Copenhagen, Denmark
48. I. Kryachok, I. Titorenko, T. Kadnikova, K. Filonenko, **T. Skrypets**, Y. Kushchevyy, I. Pastushenko, O. Aleksik, K. Ulianchenko, O. Novosad, A. Martynchyk, I. Stepanishyna, A. Novdah
Palliative chemotherapy PEPC (prednisolone, etoposide, procarbazine and cyclophosphamide) is effective and tolerable in patients with relapsed/refractory lymphomas.
Abstract book, Abstract E1451, Haematologica|2016; 101 (s1), p. 600
ESMO 2016, Copenhagen, Denmark
49. **Skrypets T.**
BRAF-v600e and p53 mutation as a potential prognostic markers of remission duration.
Abstract book, Abstract 475
EHA 2015, Viena, Austria
50. Irina Kryachok, Natalia Khranovska, Olga Novosad, Nataliia Svergun, **Tetiana Skrypets**, Tatiana Kadnikova, Irina Tytorenko, Olena Aleksik
Expression of PD-L1 ligands for Classical Hodgkin Lymphoma prognosis.
Abstract: E1140
EHA 2015, Viena, Austria

51. Irina Kryachok, Iana Stepanishina, Kateryna Filonenko, Olga Novosad, Irina Tytorenko, **Tetiana Skrypets**.

R-DA-EPOCH in patients with primary mediastinal large B-cell lymphoma: interim results of randomized (prospective) multicenter study.

Abstract: E989 EHA 2015, Viena, Austria



Bari, 20.05.2024

Tetiana Skrypets

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196
"Codice in materia di protezione dei dati personali"